NSNatalie Jane Shiff

Natalie Jane Shiff

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Natalie Jane Shiff has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Trends in Population‐Based Incidence and Prevalence of Juvenile Idiopathic Arthritis in Manitoba, Canada

    by Natalie J. Shiff, Kiem Oen, Kristine Kroeker, Lisa M. Lix

    Objective: To estimate the incidence and prevalence of juvenile idiopathic arthritis (JIA) in children ages P = 0.0292) but no statistically significant change in incidence (–0.46 [95% CI –0.94, 0.01]; P = 0.0571). Sex‐stratified models revealed a decrease for males in both prevalence (estimate –0.54 [95% CI –0.84, –10.25]; P = 0.0003) and incidence (estimate –1.02 [95% CI –2.02, –0.04]; P = 0.0439); there were no changes for females.Conclusion: Few population‐based longitudinal epidemiologic studies of JIA have been conducted. Our findings suggested a decrease in overall JIA prevalence, and in incidence and prevalence in men. Further research to validate these findings in other cohorts and to explore factors that contribute to this change will benefit future health care planning for JIA.


  • Open Access

    Growth and weight gain in children with juvenile idiopathic arthritis: results from the ReACCh-Out cohort

    by Jaime Guzman, Tristan Kerr, Leanne M. Ward, Jinhui Ma, Kiem Oen, Alan M. Rosenberg, Brian M. Feldman, Gilles Boire, Kristin Houghton, Paul Dancey, et al.

    With modern treatments, the effect of juvenile idiopathic arthritis (JIA) on growth may be less than previously reported. Our objective was to describe height, weight and body mass index (BMI) development in a contemporary JIA inception cohort. Canadian children newly-diagnosed with JIA 2005–2010 had weight and height measurements every 6 months for 2 years, then yearly up to 5 years. These measurements were used to calculate mean age- and sex-standardized Z-scores, and estimate prevalence and cumulative incidence of growth impairments, and the impact of disease activity and corticosteroids on growth. One thousand one hundred forty seven children were followed for median 35.5 months. Mean Z-scores, and the point prevalence of short stature (height < 2.5th percentile, 2.5% to 3.4%) and obesity (BMI > 95th percentile, 15.8% to 16.4%) remained unchanged in the whole cohort. Thirty-three children (2.9%) developed new-onset short stature, while 27 (2.4%) developed tall stature (>97.5th percentile). Children with systemic arthritis (n = 77) had an estimated 3-year cumulative incidence of 9.3% (95%CI: 4.3–19.7) for new-onset short stature and 34.4% (23–49.4) for obesity. Most children (81.7%) received no systemic corticosteroids, but 1 mg/Kg/day prednisone-equivalent maintained for 6 months corresponded to a drop of 0.64 height Z-scores (0.56–0.82) and an increase of 0.74 BMI Z-scores (0.56–0.92). An increase of 1 in the 10-cm physician global assessment of disease activity maintained for 6 months corresponded to a drop of 0.01 height Z-scores (0–0.02). Most children in this modern JIA cohort grew and gained weight as children in the general population. About 1 in 10 children who had systemic arthritis, uncontrolled disease and/or prolonged corticosteroid use, had increased risk of growth impairment.


  • Chronic inflammatory arthritis prevalence estimates for children and adolescents in three Canadian provinces

    by Natalie Jane Shiff, Lisa M. Lix, Kiem Oen, Lawrence Joseph, Ciaran Duffy, Elizabeth Stringer, Lori B. Tucker, Lawrence W. Svenson, Patrick Belisle, Sasha Bernatsky

    There is a paucity of published population-based estimates of the prevalence of chronic inflammatory arthritis in the pediatric population. We used administrative health data to estimate the prevalence of chronic inflammatory arthritis in individuals ≤18 years in three Canadian provinces: Quebec, Manitoba, and Saskatchewan. Cases aged ≤18 years were identified by meeting any one of the following criteria: (a) ≥1 hospital discharge abstract with an ICD-9 code of 714 or ICD-10-CA codes of M05, M06 or M08, or (b) ≥2 ICD-9 714 billing codes ≥8 weeks apart, but within 2 years, or (c) ≥1 ICD-9 714 billing code by a rheumatologist. Crude prevalence estimates per 10,000 population were estimated with 95 % confidence intervals (CIs). Prevalence estimates were 11.7 per 10,000 individuals ≤18 years of age in Manitoba, 9.8 per 10,000 in Saskatchewan, and 8.0 per 10,000 in Quebec. In pairwise comparisons of rate differences, Manitoba and Saskatchewan had higher estimates than Quebec. Prevalence estimates were higher for females than males, with a difference of 5.9 cases per 10,000 residents (95 % CI 5.1, 6.7). Saskatchewan was the only province with a higher estimate in urban compared to rural residents (5.2, 95 % CI 2.5, 8.0). Variations in provincial estimates may be due to differences in underlying population characteristics. Although these estimates have face validity and are in keeping with the range of previously published pediatric prevalence estimates, studies to establish the empiric validity of case-finding algorithms are needed to advance research in pediatric chronic disease epidemiology.